Enamine And Biosolveit Embark On Exclusive Partnership

By Author: Arina Smith
Total Articles: 185
Comment this article

Enamine and BioSolveIT have joined forces to create a groundbreaking chemical space exploration platform, revolutionizing drug discovery. The strategic partnership combines Enamine's expertise as a chief research chemicals provider with BioSolveIT's software innovation. This alliance aims to reshape chemical research, offering drug hunters worldwide unparalleled benefits such as a vast array of compounds at competitive prices, rapid delivery, and reliability.

The collaboration will expand possibilities in discovering new chemical entities, covering aspects from software solutions for ligand and structure-based exploration to synthesis. Advantages include exponential growth of novel intellectual property, tailored chemical spaces, and significant savings in the drug discovery cycle.

Researchers can expect trillions of new opportunities for drug discovery, tailored chemical spaces, and substantial cost savings throughout the drug discovery cycle. The partnership capitalizes on Enamine's make-on-demand offering and BioSolveIT's advanced algorithms, enabling researchers to efficiently select, synthesize, and ship molecules of interest globally.

Professor Dr. Andrey Tolmachov, CEO of Enamine, praises BioSolveIT's virtual screening algorithms, highlighting their compatibility with Enamine's make-on-demand capabilities. Dr. Christian Lemmen, CEO of BioSolveIT, acknowledges Enamine as a leading compound sourcing supplier.

The collaboration aims to redefine drug discovery by leveraging shared knowledge to benefit researchers and patients worldwide.